TP53 and non-small cell lung carcinoma: Freire Boullosa et al. demonstrated that auranofin, an FDA-approved antirheumatic drug with anticancer properties, induces Immunogenic cell death in non-small-cell lung cancer (NSCLC) cell lines overexpressing mutant p53 [367].